- Oral presentation
- Open Access
Vancomycin-specific T Cell responses in allergic and non-allergic individuals
Clinical and Translational Allergy volume 4, Article number: O5 (2014)
The association between specific HLA alleles and risk of severe cutaneous drug hypersensitivity reactions is increasingly recognised. Vancomycin mediated pseudo-allergic 'red man syndrome' is well recognised, yet urticaria/anaphylaxis is uncommon and some clinical reactions are delayed. Although this may suggest the presence of vancomycin initiated T cell responses, no predisposing vancomycin HLA association has been identified. Therefore we set out to examine the role of T cell responses in vancomycin hypersensitivity reactions.
Of our tested cohort of 103 individuals who suffered delayed skin drug hypersensitivity reactions, vancomycin was deemed the culprit in 17, who developed drug exanthems (59%), DRESS (35%), or SJS/TEN (18%). We used ELISpot and [3H]-Thymidine assays to measure vancomycin-specific ex-vivo IFN-/ IL-4 and proliferation above background.
Individuals with drug hypersensitivity showed a mean circulating PBMC frequency of vancomycin-specific cells of 470.0 x10-4% (IFN-) / 33.5 x10-4% (IL-4) and SI 4.08 if tested within 30 days, whilst those tested after 30 days showed 316.0 x10-4% (IFN-) / 20.0 x10-4% (IL-4) and SI 3.43. Individuals never previously exposed to vancomycin (n=11) showed a lower mean circulating frequency: 2.1 x10-4% (IFN-, p<0.005)) / 1.7 x10-4% (IL-4, p=0.27) and SI 1.28. In controls who had been exposed to vancomycin (without any evidence of a hypersensitivity reaction, n=6) detectable frequencies were also lower than allergics: 11 x10-4% (IFN-) / 7.1 x10-4% (IL-4) and SI 0.98. We co-cultured non-allergic PBMC with vancomycin for two-weeks in vitro. In two lines, we saw expansion of vancomycin-specific T cells in ELISpot to an average frequency of 954 x10-4% (IFN-) and 1130 x10-4% (IL-4) which was confirmed by ELISpot and intracellular cytokine staining.
These data confirm that robust Th1 responses target vancomycin in cutaneous hypersensitivity reactions, which supports the use of T cell inhibition such as steroids and ciclosporin. Vancomycin-specific responses appear reduced with time which advocates early diagnostic testing, but the clinical possibility of loss of sensitisation is intriguing. The finding that vancomycin-specific T cells can be artificially expanded from individuals without clinical reactivity, suggests that both immune predisposition and potentially adaptive regulation may be important in development of hypersensitivity responses to vancomycin.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Polak, M.E., McGuire, C., Lee, A. et al. Vancomycin-specific T Cell responses in allergic and non-allergic individuals. Clin Transl Allergy 4 (Suppl 3), O5 (2014). https://doi.org/10.1186/2045-7022-4-S3-O5
- Hypersensitivity Reaction
- Intracellular Cytokine Staining
- Drug Hypersensitivity Reaction
- Cutaneous Hypersensitivity